Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2015

  1. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections

    International Journal of Pharmaceutics, Vol. 494, Núm. 1, pp. 17-22

2014

  1. Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose

    Drug Design, Development and Therapy, Vol. 8, pp. 1467-1479

2012

  1. The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treat-ments

    Current Drug Metabolism, Vol. 13, Núm. 9, pp. 1303-1312

2011

  1. Changed crystallinity of mebendazole solid dispersion: Improved anthelmintic activity

    International Journal of Pharmaceutics, Vol. 403, Núm. 1-2, pp. 23-28

2008

  1. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers

    Pharmacological Research, Vol. 58, Núm. 1, pp. 77-84